Haritha H , Nair and Ruby John , Anto (2015) Triple negative breast cancer: The therapeutic windows yet to be opened? Science Letters , 4 (175). ISSN 2454 – 7239

Text triple negative breast cancer(science letters).pdf Restricted to Registered users only Download (318Kb) | Request a copy

Abstract

Triple negative breast cancers (TNBCs) are generally diagnosed based on the absence of three receptors known to fuel most breast cancers: estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2). These tumors, being tagged „triple negative‟, exhibit non-responsiveness towards receptor targeted treatments, are particularly aggressive, invasive, metastatic and more likely to recur than other subtypes of breast cancer. It has a high rate of prevalence among young women, especially those of African-American descent. The molecular profiling data suggests an overlap between triple negative and basal-like subtypes of breast cancers. Though targeted therapies are not yet available, combination chemotherapy was found to be effective against triple negative breast cancer. This review gives a comprehensive description of triple negative and basal–like breast cancers, their genetic and molecular signatures, the advantages and disadvantages of currently available treatments and possible therapeutic interventions that may ascend the survival rate.

Item Type:	Article
Uncontrolled Keywords:	Triple negative breast cancer; Basal-like breast cancer; Chemotherapy; Targeted therapy; Chemosensitization
Subjects:	Cancer Research
Depositing User:	Central Library RGCB
Date Deposited:	19 Mar 2018 06:32
Last Modified:	19 Mar 2018 06:32
URI:	http://rgcb.sciencecentral.in/id/eprint/527

Actions (login required)

View Item